1
|
Agnol RD, Dos Santos MT, Michalowski MB, Einsfeld L. Pharmacists' interventions on 2 years of drug monitoring in an oncology pediatric inpatient ward. J Oncol Pharm Pract 2021; 28:1754-1762. [PMID: 34605321 DOI: 10.1177/10781552211041037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND In oncology, pharmacists contribute to safety and effectiveness of drug treatment, identifying, preventing and forwarding solutions to drug-related problems (DRPs). However, it is still necessary to elucidate the profile of drug-related problems in pediatric cancer treatment to contribute to guide clinical pharmacy activities. METHODS A retrospective cross-sectional study was conducted. Records on Excel® spreadsheets of 2 years of pharmaceutical assistance were analyzed regarding the prescriptions of chemotherapy for hospitalized patients aged 0-19 years. Data on age, sex, cancer diagnosis, protocol and drugs prescribed were collected. Causes and types of DRPs and pharmacists' interventions as their rate of acceptance were measured according to PCNE V 9.0. RESULTS Drug-related problems were identified for 84 patients, in 5.3% of analyzed prescriptions. Leukemias, patients aged 0-4 years and male sex were associated with higher rates of drug-related problems. The BFM 2009 protocol for acute lymphocytic leukemia treatment had the highest frequency of prescriptions with drug-related problems. Main drug-related problems were related to effectiveness (49.2%) and safety (33.2%), with most of them due to drug selection and dose. Rate of acceptance of interventions was 92.2% and 90.6% of drug-related problems were fully resolved. Mercaptopurine and filgrastim were the drugs most associated with drug-related problems. Oral antineoplastic agents represented 36% of the prescriptions with drug-related problems. CONCLUSION The high rate of acceptance of pharmacist interventions demonstrates the relevance of the pharmacist participation in the care of hospitalized pediatric patients undergoing chemotherapy. Pharmacists need to take attention to cases of necessity of drug prescription, intervening with other health professionals. Special attention to oral chemotherapy is required.
Collapse
Affiliation(s)
- Rafaela Dall Agnol
- Pharmacy Service, Clinical Pharmacy Section, 37895Hospital de Clínicas de Porto Alegre, Brazil
| | - Maitê T Dos Santos
- Postgraduate Program in Child and Adolescent Health, 28124Federal University of Rio Grande do Sul, Brazil
| | - Mariana B Michalowski
- Department of Pediatrics, Federal University of Rio Grande do Sul and Pediatric Oncology Service, Hospital de Clínicas de Porto Alegre, Brazil
| | - Lídia Einsfeld
- Pharmacy Service, Clinical Pharmacy Section, 37895Hospital de Clínicas de Porto Alegre, Brazil
| |
Collapse
|
2
|
Field MT, Lamble AJ, Holtzclaw SL, Tucker SA, Ketterl TG. Chemotherapy roadmaps in pediatric oncology: A digital electronic medical record integrated solution. J Oncol Pharm Pract 2021; 28:1722-1730. [PMID: 34558367 DOI: 10.1177/10781552211040450] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Delivery of antineoplastic regimens in the pediatric setting is facilitated by a paper roadmap. Paper roadmaps are the key safety tool required for safe ordering. Electronic medical record systems offer technological solutions for ordering antineoplastic regimens, however, do not offer a solution that integrates paper roadmaps digitally. METHODS A multidisciplinary project team implemented real-time clinician scanning of paper roadmaps into the electronic medical record. RESULTS The rate of missing roadmaps decreased from an average of 1.6 to 0.8 per week. Pharmacists gained 3 h of productivity daily. Providers spend an average of 35-45 s and a total of seven clicks each time a roadmap is scanned. Overall, the clinical systems analyst spent less than 1 h of total build time. CONCLUSION Implementing roadmap scanning decreased the rate of missing roadmaps, increased pharmacist productivity, and required a nominal amount of analyst and provider time. In addition, this solution allows for concurrent viewing of the roadmap files from any connected computer, facilitating an easier co-signature process for providers, pharmacists, and nurses. PRACTICE IMPLICATIONS These results suggest that implementing real-time scanning of roadmaps can improve oncology care efficiency while maintaining the same safety rigor that paper roadmaps offer.
Collapse
Affiliation(s)
- Mary T Field
- Cancer and Blood Disorders Center, Seattle Children's Hospital, USA
| | - Adam J Lamble
- Cancer and Blood Disorders Center, Seattle Children's Hospital, USA.,Division of Pediatric Hematology/Oncology, Department of Pediatrics, 7284University of Washington, USA
| | | | - Sarah A Tucker
- Cancer and Blood Disorders Center, Seattle Children's Hospital, USA
| | - Tyler G Ketterl
- Cancer and Blood Disorders Center, Seattle Children's Hospital, USA.,Division of Pediatric Hematology/Oncology, Department of Pediatrics, 7284University of Washington, USA
| |
Collapse
|
3
|
Interventions to Reduce Pediatric Prescribing Errors in Professional Healthcare Settings: A Systematic Review of the Last Decade. Paediatr Drugs 2021; 23:223-240. [PMID: 33959936 DOI: 10.1007/s40272-021-00450-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 04/16/2021] [Indexed: 10/21/2022]
Abstract
INTRODUCTION Pediatric medication therapy is prone to errors due to the need for pharmacokinetic and pharmacodynamic individualization and the diverse settings in which pediatric patients are treated. Prescribing errors have been reported as the most common medication error. OBJECTIVES The aim of this review was to systematically identify interventions to reduce prescribing errors and corresponding patient harm in pediatric healthcare settings and to evaluate their impact. METHODS Four databases were systematically screened (time range November 2011 to December 2019), and experimental studies were included. Interventions to reduce prescribing errors were extracted and classified according to a 'hierarchy of controls' model. RESULTS Forty-five studies were included, and 70 individual interventions were identified. A bundle of interventions was more likely to reduce prescribing errors than a single intervention. Interventions classified as 'substitution or engineering controls' were more likely to reduce errors in comparison with 'administrative controls', as is expected from the hierarchy of controls model. Fourteen interventions were classified as substitution or engineering controls, including computerized physician order entry (CPOE) and clinical decision support (CDS) systems. Administrative controls, including education, expert consultations, and guidelines, were more commonly identified than higher level controls, although they may be less likely to reduce errors. Of the administrative controls, expert consultations were most likely to reduce errors. CONCLUSIONS Interventions to reduce pediatric prescribing errors are more likely to be successful when implemented as part of a bundle of interventions. Interventions including CPOE and CDS that substitute risks or provide engineering controls should be prioritized and implemented with appropriate administrative controls including expert consultation.
Collapse
|
4
|
The Cancer Care Index: A Novel Metric to Assess Overall Performance of a Pediatric Oncology Program. J Patient Saf 2021; 16:e120-e125. [PMID: 27314203 DOI: 10.1097/pts.0000000000000267] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
OBJECTIVE Childhood cancer metrics are currently primarily focused on survival rates and late effects of therapy. Our objectives were to design and test a metric that reflected overall quality and safety performance, across all cancer types, of an oncology-bone marrow transplant service line and to use the metric to drive improvement. METHOD The Cancer Care Index (CCI) aggregates adverse safety events and missed opportunities for best practices into a composite score that reflects overall program performance without regard to cancer type or patient outcome. Fifteen domains were selected in 3 areas as follows: (1) treatment-related quality and safety, (2) provision of a harm-free environment, and (3) psychosocial support. The CCI is the aggregate number of adverse events or missed opportunities to provide quality care in a given time frame. A lower CCI reflects better care and improved overall system performance. Multidisciplinary microsystem-based teams addressed specific aims for each domain. The CCI was widely followed by all team members, particularly frontline providers. RESULTS The CCI was easy to calculate and deploy and well accepted by the staff. The annual CCI progressively decreased from 278 in 2012 to 160 in 2014, a 42% reduction. Improvements in care were realized across most index domains. Multiple new initiatives were successfully implemented. CONCLUSIONS The CCI is a useful metric to document performance improvement across a broad range of domains, regardless of cancer type. By the use of quality improvement science, progressive reduction in CCI has occurred over a 3-year period.
Collapse
|
5
|
Bannan DF, Aseeri MA, AlAzmi A, Tully MP. Prescriber behaviours that could be targeted for change: An analysis of behaviours demonstrated during prescription writing in children. Res Social Adm Pharm 2021; 17:1737-1749. [PMID: 33514496 DOI: 10.1016/j.sapharm.2021.01.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2019] [Revised: 01/17/2021] [Accepted: 01/17/2021] [Indexed: 11/25/2022]
Abstract
BACKGROUND The prescribing process for children with cancer is complex, and errors can occur at any step. As a result, many interventions have been used to reduce errors. However, few of them have been designed based on an understanding of the prescriber behaviour that can lead to errors. In order to design effective behaviour change interventions, it is important first to understand the prescribing process and identify prescriber behaviours that could be targeted for change. OBJECTIVES To describe the prescribing process in a paediatric oncology ward and to identify prescriber behaviours during prescription writing that could be targeted to reduce errors. METHODS This study employed two sequential phases. First, the prescribing process was observed and then described using the hierarchical task analysis (HTA) method. Second, prescriber tasks identified from the HTA were analysed using the behaviour change wheel (BCW) approach to identify promising behaviours for change. These identified behaviours were prioritised based on information collected from four focus groups with prescribers and chart review of errors made in the ward. RESULTS The prescribing process was complex and involved multiple tasks performed in varying orders. Applying the BCW identified thirty-two candidate behaviours for potentially reducing prescribing errors. However, after prioritization, only two emerged as promising candidate behaviours for intervention: writing drug indications at the time of prescribing and using a pre-written order when ordering medications through electronic prescribing. CONCLUSIONS This research suggests that two behaviours could be promising in reducing errors. Having identified these behaviours, future work could explore what needs to change with respect to individuals and their work environments to achieve the desired change in these identified behaviours.
Collapse
Affiliation(s)
| | - Mohammed A Aseeri
- Pharmacy Department, King Saud Bin Abdul Aziz University for Health Sciences, King Abdul Aziz Medical City, National Guard Health Affairs, Jeddah, Saudi Arabia
| | - Aeshah AlAzmi
- Pharmacy Department, King Abdul Aziz Medical City, National Guard Health Affairs, Jeddah, Saudi Arabia
| | - Mary P Tully
- School of Health Science, Division of Pharmacy and Optometry, University of Manchester, Manchester, UK
| |
Collapse
|
6
|
Koeck JA, Young NJ, Kontny U, Orlikowsky T, Bassler D, Eisert A. Interventions to Reduce Medication Dispensing, Administration, and Monitoring Errors in Pediatric Professional Healthcare Settings: A Systematic Review. Front Pediatr 2021; 9:633064. [PMID: 34123962 PMCID: PMC8187621 DOI: 10.3389/fped.2021.633064] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Accepted: 04/12/2021] [Indexed: 11/18/2022] Open
Abstract
Introduction: Pediatric patients cared for in professional healthcare settings are at high risk of medication errors. Interventions to improve patient safety often focus on prescribing; however, the subsequent stages in the medication use process (dispensing, drug administration, and monitoring) are also error-prone. This systematic review aims to identify and analyze interventions to reduce dispensing, drug administration, and monitoring errors in professional pediatric healthcare settings. Methods: Four databases were searched for experimental studies with separate control and intervention groups, published in English between 2011 and 2019. Interventions were classified for the first time in pediatric medication safety according to the "hierarchy of controls" model, which predicts that interventions at higher levels are more likely to bring about change. Higher-level interventions aim to reduce risks through elimination, substitution, or engineering controls. Examples of these include the introduction of smart pumps instead of standard pumps (a substitution control) and the introduction of mandatory barcode scanning for drug administration (an engineering control). Administrative controls such as guidelines, warning signs, and educational approaches are lower on the hierarchy and therefore predicted by this model to be less likely to be successful. Results: Twenty studies met the inclusion criteria, including 1 study of dispensing errors, 7 studies of drug administration errors, and 12 studies targeting multiple steps of the medication use process. A total of 44 interventions were identified. Eleven of these were considered higher-level controls (four substitution and seven engineering controls). The majority of interventions (n = 33) were considered "administrative controls" indicating a potential reliance on these measures. Studies that implemented higher-level controls were observed to be more likely to reduce errors, confirming that the hierarchy of controls model may be useful in this setting. Heterogeneous study methods, definitions, and outcome measures meant that a meta-analysis was not appropriate. Conclusions: When designing interventions to reduce pediatric dispensing, drug administration, and monitoring errors, the hierarchy of controls model should be considered, with a focus placed on the introduction of higher-level controls, which may be more likely to reduce errors than the administrative controls often seen in practice. Trial Registration Prospero Identifier: CRD42016047127.
Collapse
Affiliation(s)
- Joachim A Koeck
- Hospital Pharmacy, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany
| | - Nicola J Young
- Hospital Pharmacy, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany
| | - Udo Kontny
- Section of Pediatric Hematology, Department of Pediatric and Adolescent Medicine, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany
| | - Thorsten Orlikowsky
- Section of Neonatology, Department of Pediatric and Adolescent Medicine, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany
| | - Dirk Bassler
- Department of Neonatology, University Hospital Zurich, Zurich, Switzerland
| | - Albrecht Eisert
- Hospital Pharmacy, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany.,Institute of Clinical Pharmacology, University Hospital of Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany
| |
Collapse
|
7
|
Gates PJ, Baysari MT, Mumford V, Raban MZ, Westbrook JI. Standardising the Classification of Harm Associated with Medication Errors: The Harm Associated with Medication Error Classification (HAMEC). Drug Saf 2020; 42:931-939. [PMID: 31016678 PMCID: PMC6647434 DOI: 10.1007/s40264-019-00823-4] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Classifying harm associated with a medication error can be time consuming and labour intensive and limited studies undertake this step. There is no standardised process, and few studies that report harm assessment provide adequate methods to allow for study replication. Studies typically mention that a clinical review panel classified patient harm and provide a reference to a classification tool. Moreover, in many studies it is unclear whether potential or actual harm was classified as studies refer only to ‘error severity’. The tools used to categorise the severity of patient harm vary widely across studies and few have been assessed for inter-rater reliability and criterion validity. In this paper, we describe the systematic process we undertook to synthesise the defining elements and strengths, while mitigating the limitations, of existing harm classification tools to derive the Harm Associated with Medication Error Classification (HAMEC). This new tool provides a harm classification for use across clinical and research settings. The provision of an explicit process for its application and guiding category descriptors are designed to reduce the risk of misclassification and produce results that are comparable across studies. As the World Health Organisation embarks on its international safety challenge of reducing medication-related harm by 50%, accompanying methodological advances are required to measure progress.
Collapse
Affiliation(s)
- Peter J Gates
- Centre for Health Systems and Safety Research, Australian Institute of Health Innovation, Macquarie University, Sydney, NSW, Australia.
| | - Melissa T Baysari
- Centre for Health Systems and Safety Research, Australian Institute of Health Innovation, Macquarie University, Sydney, NSW, Australia
| | - Virginia Mumford
- Centre for Health Systems and Safety Research, Australian Institute of Health Innovation, Macquarie University, Sydney, NSW, Australia
| | - Magdalena Z Raban
- Centre for Health Systems and Safety Research, Australian Institute of Health Innovation, Macquarie University, Sydney, NSW, Australia
| | - Johanna I Westbrook
- Centre for Health Systems and Safety Research, Australian Institute of Health Innovation, Macquarie University, Sydney, NSW, Australia
| |
Collapse
|
8
|
Lichtner V, Baysari M, Gates P, Dalla-Pozza L, Westbrook JI. Medication safety incidents in paediatric oncology after electronic medication management system implementation. Eur J Cancer Care (Engl) 2019; 28:e13152. [PMID: 31436876 PMCID: PMC7161912 DOI: 10.1111/ecc.13152] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2019] [Revised: 07/22/2019] [Accepted: 08/01/2019] [Indexed: 11/30/2022]
Abstract
Objective To explore medication safety issues related to use of an electronic medication management system (EMM) in paediatric oncology practice, through the analysis of patient safety incident reports. Methods We analysed 827 voluntarily reported incidents relating to oncology patients that occurred over an 18‐month period immediately following implementation of an EMM in a paediatric hospital in Australia. We identified medication‐related and EMM‐related incidents and carried out a content analysis to identify patterns. Results We found ~79% (n = 651) of incidents were medication‐related and, of these, ~45% (n = 294) were EMM‐related. Medication‐related incidents included issues with: prescribing; dispensing; administration; patient transfers; missing chemotherapy protocols and information on current stage of patient treatment; coordination of chemotherapy administration; handling or storing medications; children or families handling medications. EMM‐related incidents were classified into four groups: technical issues, issues with the user experience, unanticipated problems in EMM workflow, and missing safety features. Conclusions Incidents reflected difficulties with managing therapies rich in interdependencies. EMM, and especially its ‘automaticity’, contributed to these incidents. As EMM impacts on safety in such high‐risk settings, it is essential that users are aware of and attend to EMM automatic behaviours and are equipped to troubleshoot them.
Collapse
Affiliation(s)
- Valentina Lichtner
- Department of Practice and Policy, School of Pharmacy, UCL, London, UK.,Centre for Health Systems and Safety Research, AIHI, Macquarie University, Sydney, NSW, Australia
| | - Melissa Baysari
- Centre for Health Systems and Safety Research, AIHI, Macquarie University, Sydney, NSW, Australia.,Faculty of Health Sciences, University of Sydney, Sydney, Australia
| | - Peter Gates
- Centre for Health Systems and Safety Research, AIHI, Macquarie University, Sydney, NSW, Australia
| | - Luciano Dalla-Pozza
- Cancer Centre for Children, The Children Hospital at Westmead, Sydney, Australia
| | - Johanna I Westbrook
- Centre for Health Systems and Safety Research, AIHI, Macquarie University, Sydney, NSW, Australia
| |
Collapse
|
9
|
Azim M, Khan A, Khan TM, Kamran M. A cross-sectional study: medication safety among cancer in-patients in tertiary care hospitals in KPK, Pakistan. BMC Health Serv Res 2019; 19:583. [PMID: 31426786 PMCID: PMC6699127 DOI: 10.1186/s12913-019-4420-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2019] [Accepted: 08/09/2019] [Indexed: 12/01/2022] Open
Abstract
Background Medication safety in cancer patients receiving complex medication regimens is an important problem in various settings. Medication related events, interceptions and interventions are not well described in this area. We intended to study incidence, types, settings and stages involved, root cause analysis, medication classes involved and the level of harm cause by medication errors in two hospitals providing oncology services comparatively. The severity of incidents and interventions are studied. Methods It was a prospective cross sectional study among cancer in-patients of two tertiary care hospitals of KPK. Scale by NCC-MERP was used for evaluation of all medication related incidents. The data obtained was analyzed by IBM SPSS statistics 22 with 95% confidence interval and used the same for other descriptive statistics. Results All medication orders were reviewed at both sites (Computerized Prescription Order Entry and HWP systems). Potential ADEs incidence was found high at site 2 (97.5%) while medication errors without harm was high at site 1 (97.5%). Most events occur at prescribing level 87.6 and 81.7% at both sites 1 and 2. Types highly reported involved improper dose 31.4 and 15.5%, monitoring error 14.6 and 15.2% at site 1 and 2. Medications involved in these incidents were antibiotics 44 and 12.7%, antiemetic 7.5 and 15.8% and antineoplastic 2.9 and 9.4% at site 1 and 2. Severity of 3.6 and 36.5% incidents had potential to cause harm at site 1 and 2. Root causes were human factors 62.6 and 72.3%, drug selection 33.6 and 38.8%, and dose selection 39.6 and 15.3% at sites 1 and 2. Contributing factors including staff training 33.6 and 24.3%, system for covering patient care 14.9 and 36.6%, communication system 2.4 and 20.3%, interruptions 9.7 and 7.3% and others 78.8 and 68.6% were highly reported. Preventability of medication errors was 99% at both sites. Intervention was taken in 90.5% events at site 1 (CPOE system) while the incidence lowest at site 2 (HWP system). Conclusion Medication related events are high among cancer in-patients at the site lacking updated electronic system for medication prescribing. Proper training about medication safety, reporting and interventions are required.
Collapse
Affiliation(s)
- Marium Azim
- Quaid-I-Azam University, QAU Islamabad, Islamabad, Pakistan.
| | - Ahmad Khan
- Department of Pharmacy, Qauid-I-Azam University, QAU Islamabad, Islamabad, Pakistan
| | | | - Mohammad Kamran
- Riphah International University Islamabad, Islamabad, Pakistan
| |
Collapse
|
10
|
Weingart SN, Zhang L, Sweeney M, Hassett M. Chemotherapy medication errors. Lancet Oncol 2019; 19:e191-e199. [PMID: 29611527 DOI: 10.1016/s1470-2045(18)30094-9] [Citation(s) in RCA: 116] [Impact Index Per Article: 23.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2017] [Revised: 12/07/2017] [Accepted: 12/14/2017] [Indexed: 11/26/2022]
Abstract
Although chemotherapy is a well established treatment modality, chemotherapy errors represent a potentially serious risk of patient harm. We reviewed published research from 1980 to 2017 to understand the extent and nature of medication errors in cancer chemotherapy, and to identify effective interventions to help prevent mistakes. Chemotherapy errors occur at a rate of about one to four per 1000 orders, affect at least 1-3% of adult and paediatric oncology patients, and occur at all stages of the medication use process. Oral chemotherapy use is a particular area of growing risk. Our knowledge of chemotherapy errors is drawn primarily from single-institution studies at university hospitals and referral centres, with a particular focus on prescription orders and pharmacy practices. Although the heterogeneity of research methods and measures used in these studies limits our understanding of this issue, the rate of chemotherapy error-related injuries is generally lower than those seen in comparable studies of general medical patients. Although many interventions show promise in reducing chemotherapy errors, most have little empirical support. Additional research is needed to understand and to mitigate the risk of chemotherapy medication errors.
Collapse
Affiliation(s)
- Saul N Weingart
- Tufts Medical Center and Tufts University School of Medicine, Boston, MA, USA.
| | - Lulu Zhang
- Tufts Medical Center and Tufts University School of Medicine, Boston, MA, USA
| | - Megan Sweeney
- Tufts Medical Center and Tufts University School of Medicine, Boston, MA, USA
| | - Michael Hassett
- Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA
| |
Collapse
|
11
|
Lê L, Berge M, Tfayli A, Baillet Guffroy A, Prognon P, Dowek A, Caudron E. Quantification of gemcitabine intravenous drugs by direct measurement in chemotherapy plastic bags using a handheld Raman spectrometer. Talanta 2018; 196:376-380. [PMID: 30683379 DOI: 10.1016/j.talanta.2018.11.062] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2018] [Revised: 11/17/2018] [Accepted: 11/19/2018] [Indexed: 11/28/2022]
Affiliation(s)
- L Lê
- U-Psud, Univ. Paris-Saclay, Lip(Sys)2 Chimie Analytique Pharmaceutique, EA7357, UFR-Pharmacy, Châtenay-Malabry, France; European Georges Pompidou Hospital (AP-HP), Pharmacy Department, 20 rue Leblanc, 75015 Paris, France.
| | - M Berge
- European Georges Pompidou Hospital (AP-HP), Pharmacy Department, 20 rue Leblanc, 75015 Paris, France
| | - A Tfayli
- U-Psud, Univ. Paris-Saclay, Lip(Sys)2 Chimie Analytique Pharmaceutique, EA7357, UFR-Pharmacy, Châtenay-Malabry, France
| | - A Baillet Guffroy
- U-Psud, Univ. Paris-Saclay, Lip(Sys)2 Chimie Analytique Pharmaceutique, EA7357, UFR-Pharmacy, Châtenay-Malabry, France
| | - P Prognon
- U-Psud, Univ. Paris-Saclay, Lip(Sys)2 Chimie Analytique Pharmaceutique, EA7357, UFR-Pharmacy, Châtenay-Malabry, France; European Georges Pompidou Hospital (AP-HP), Pharmacy Department, 20 rue Leblanc, 75015 Paris, France
| | - A Dowek
- European Georges Pompidou Hospital (AP-HP), Pharmacy Department, 20 rue Leblanc, 75015 Paris, France
| | - E Caudron
- U-Psud, Univ. Paris-Saclay, Lip(Sys)2 Chimie Analytique Pharmaceutique, EA7357, UFR-Pharmacy, Châtenay-Malabry, France; European Georges Pompidou Hospital (AP-HP), Pharmacy Department, 20 rue Leblanc, 75015 Paris, France
| |
Collapse
|
12
|
Mulatsih S, Dwiprahasto I, Sutaryo. Implementation of Medication Safety Practice in Childhood Acute Lymphoblastic Leukemia Treatment. Asian Pac J Cancer Prev 2018; 19:1251-1257. [PMID: 29801409 PMCID: PMC6031849 DOI: 10.22034/apjcp.2018.19.5.1251] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Objective: Medical Safety Practice (MSP) is a safe procedure in medication process. It is important to investigate the use of MSP among childhood cancer patients because pediatric oncology is a high-risk area for potentially harmful adverse events. The purpose of this study is to determine the effects of the implementation of MSP in chemotherapy on the incidence of medication errors in childhood ALL patient at Dr. Sardjito Hospital, including in 1) transcribing, 2) administering, 3) monitoring, 4) the incidence of adverse drugs events. (ADEs). Methods: The study design is a quasi-experimental study with pre- and post-intervention without control. The sample consists of ALL patients who are taken care of at an academic hospital in Indonesia from 2012 to 2013. The sample was consecutively collected during the period of study. The data were collected through medical records, research form, observation, and discussion with the nurse. The intervention given is training and implementation of medical safety practice in chemotherapy. Result: Based on the analysis of the effect of the implementation of MSP (75 and 106 medical records of pre- and post-intervention), it is obtained: 1) the adherence of chemotherapy transcribing post-intervention increases significantly compared to pre-intervention (p<0.05), 2) the adherence of chemotherapy administering increases significantly in almost every aspect (p<0.05), except in preparing drugs by two different health worker, patient’s confirmation of ADEs management, and verification of drug’s expired date, 3) The adherence of chemotherapy monitoring improved significantly post-intervention (p<0.05), 4) Adverse Drug Events (ADE) decreased significantly post-intervention (p<0.05), from 52.1% to 30.5%. Conclusion: The implementation of MSP decreased the incidence of medication errors in ALL patients at Dr. Sardjito Hospital in ordering, dispensing, transcribing, administering, and monitoring chemotherapy. It also reduced the incidence of ADEs related to chemotherapy. Specific training for nurses are needed in order to improve the knowledge and skills, especially for medication error and skill in patients’ care.
Collapse
Affiliation(s)
- Sri Mulatsih
- Department of Pediatrics, Faculty of Medicine, Universitas Gadjah Mada/ Dr. Sardjito Hospital, Yogyakarta, Indonesia.
| | | | | |
Collapse
|
13
|
Hamel C, Tortolano L, Bermudez E, Desmaris R, Klein S, Slimano F, Lemare F. Computerized pediatric oncology prescriptions review by pharmacist: A descriptive analysis and associated risk factors. Pediatr Blood Cancer 2018; 65. [PMID: 29251399 DOI: 10.1002/pbc.26897] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/26/2017] [Revised: 10/23/2017] [Accepted: 10/23/2017] [Indexed: 11/08/2022]
Abstract
BACKGROUND Systematic prescription analyses by clinical pharmacists result in pharmacist interventions (PIs) to reduce prescription errors and improve medication safety. PIs are particularly critical in oncology, because antineoplastic drugs are highly toxic with low therapeutic indexes especially in a pediatric population. The aim of this study is to describe PIs in a pediatric oncology department and to identify potential risk factors associated with prescription errors. PROCEDURE We conducted a 20-month observational study in a pediatric oncology department concerning electronic prescription of injectable chemotherapies was conducted. PIs were analyzed for drug-related problems (DRPs), type of intervention, population characteristics, involved drugs, and the potential risk factors. RESULTS Clinical pharmacists made 90 PIs for 10,214 antineoplastic prescriptions for a rate of 88 PIs per 10,000 prescriptions. The majority of DRPs were dosage errors (61.8%), imputable to measurements (weight and/or height) in 47.4% or unreported dose reduction. The most common patient ages were in the range 1-10 years and the most common time for medical double checks was 2-9 pm. There were statistically more prescription errors in standardized protocols (P < 0.001). CONCLUSIONS Not surprisingly, PIs were predominantly to correct dose errors, half of which related to height and weight measurements that were not updated. No significant risk factors for errors were identified for errors except in the standardized status of prescription, which appears to be linked in part to our software that did not automatically reflect dose reduction from one course to the next. Medical double-checking followed by a clinical pharmacist's double check were effective in order to prevent prescription errors.
Collapse
Affiliation(s)
- Claire Hamel
- Department of Clinical Pharmacy, Gustave Roussy Cancer Campus, Villejuif Cedex, 94805, France
| | - Lionel Tortolano
- Department of Clinical Pharmacy, Gustave Roussy Cancer Campus, Villejuif Cedex, 94805, France.,EA401, IFR141, Faculty of Pharmacy, Paris-sud, University, Chatenay-Malabry, 92296, France.,Assistance Publique-Höpitaux de Paris, Groupe hospitalier Henri Mondor, Department of Pharmacy, 51 Avenue du Maréchal de Lattre de Tassigny, Créteil, F-94010, France
| | - Elisabeth Bermudez
- Department of Clinical Pharmacy, Gustave Roussy Cancer Campus, Villejuif Cedex, 94805, France
| | - Romain Desmaris
- Department of Clinical Pharmacy, Gustave Roussy Cancer Campus, Villejuif Cedex, 94805, France
| | - Sébastien Klein
- Department of Pediatric Oncology, Gustave Roussy Cancer Campus, Villejuif Cedex, 94805, France
| | - Florian Slimano
- Department of Clinical Pharmacy, Gustave Roussy Cancer Campus, Villejuif Cedex, 94805, France.,MEDyC Research Unit, UMR CNRS/URCA no. 7369, Reims University, Reims, 51100, France.,Facuty of Pharmacy, Reims University, Reims, 51100, France
| | - François Lemare
- Department of Clinical Pharmacy, Gustave Roussy Cancer Campus, Villejuif Cedex, 94805, France.,Chair of Clinical Pharmacy, Faculty of Pharmacy of Paris, Sorbonne-Paris University, Paris, 75 270, France.,EA 7348 MOS, Ecole des Hautes Etudes en Santé Publique, Rennes, 35043, France
| |
Collapse
|
14
|
Fisher CM, Kim AJ, Elder JJ. Impact of a Pharmacist-Led Chemotherapy Education Program on the Knowledge of Pediatric Hematology/Oncology Nurses. J Pediatr Pharmacol Ther 2017; 22:332-337. [PMID: 29042833 DOI: 10.5863/1551-6776-22.5.332] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
OBJECTIVES Medication errors involving chemotherapy are a serious source of avoidable medical harm that can result in chemotherapy-related adverse drug events. Efforts to reduce errors in the past decade have largely focused on chemotherapy errors at the prescriber level, using computerized or automated technology, but little has been done to ensure chemotherapy is administered accurately at the nursing level. The current study implemented a pharmacist-led, supplemental, institution-specific training program to nursing staff regarding the use of chemotherapy and to address knowledge deficits in newly hired nursing personnel. METHODS Inpatient pediatric oncology nurses were eligible to participate in a 3-session educational program regarding chemotherapy principles, adverse event management, and supportive care. Pre- and posttests were administered during the sessions to assess baseline and acquired knowledge. An attitudes survey was given to nurses prior to their first session and after the last session to assess the nurse's comfort with administration and management of chemotherapy. RESULTS Posttest scores following program implementation show a significant increase in baseline knowledge. Scores increased by 14.1% (p < 0.001) overall; they increased 6% (p = 0.266), 22% (p = <0.001), and 16.5% (p = <0.001) after sessions 1, 2, and 3, respectively. All respondents requested additional classes for orientation or continuing education. CONCLUSIONS A pharmacist-led, educational program significantly improves knowledge of chemotherapy administration and monitoring in pediatric oncology nurses and was well received by participants as an additional training opportunity.
Collapse
Affiliation(s)
- Christine M Fisher
- Department of Pharmacy (CMF, AJK, JJE), Norton Children's Hospital, Louisville, Kentucky, Department of Pharmacy (AJK), Children's Hospital Colorado, Aurora, Colorado
| | - Abby J Kim
- Department of Pharmacy (CMF, AJK, JJE), Norton Children's Hospital, Louisville, Kentucky, Department of Pharmacy (AJK), Children's Hospital Colorado, Aurora, Colorado
| | - Joshua J Elder
- Department of Pharmacy (CMF, AJK, JJE), Norton Children's Hospital, Louisville, Kentucky, Department of Pharmacy (AJK), Children's Hospital Colorado, Aurora, Colorado
| |
Collapse
|
15
|
Blignaut AJ, Coetzee SK, Klopper HC, Ellis SM. Medication administration errors and related deviations from safe practice: an observational study. J Clin Nurs 2017; 26:3610-3623. [PMID: 28102918 DOI: 10.1111/jocn.13732] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/25/2016] [Indexed: 11/27/2022]
Abstract
AIMS AND OBJECTIVES To determine the incidence of medication administration errors, medication administration-related deviations from safe practice as well as factors associated with these errors in medical and surgical units of public hospitals in the Gauteng Province of South Africa. BACKGROUND Several studies have been published on the incidence of medication administration errors, but only a few have studied the incidence of medication administration-related deviations from safe practice. Context-specific research on the incidence of medication administration errors and associated factors (patient acuity, bed occupancy, staffing levels, medication administrators' qualifications, dose calculation skills, level of hospital, unit type, medication administration route and interruptions) within the continent of Africa is lacking. DESIGN A cross-sectional, observational design. METHODS Direct observation was conducted incorporating a previously validated checklist based on basic medication guidelines including the five rights, asepsis and medication documentation. In addition, a knowledge test on dose calculations was performed. Medication administration to 315 patients (1847 medications administered) was observed between February-August 2015 in medical and surgical units from eight public hospitals. Twenty-five medication administrators completed dose calculations. RESULTS In total, 296 medication errors were identified, of which most were wrong-time errors and omissions. Interruptions and patient acuity were significantly associated with wrong-dose and wrong-route errors, respectively. Most medication administration-related deviations from safe practice were related to patient identification or asepsis. Sixteen of 50 dosage calculations were answered incorrectly. Incorrect answers most often occurred in the calculation of parenteral dosages. CONCLUSIONS Medication administration errors, especially wrong-time errors and omissions, are prevalent in public hospitals in the Gauteng Province. Interruptions lower the risk of wrong-dose errors, while patient acuity exacerbates this risk. RELEVANCE TO CLINICAL PRACTICE Factors associated with wrong-time errors and omissions should be addressed. Patient identification and asepsis protocols should be adhered to. Dosage calculation training is indicated.
Collapse
Affiliation(s)
- Alwiena J Blignaut
- School of Nursing Science, North-West University (Potchefstroom Campus), Potchefstroom, South Africa
| | - Siedine K Coetzee
- School of Nursing Science, North-West University (Potchefstroom Campus), Potchefstroom, South Africa
| | - Hester C Klopper
- INSINQ Research Unit, North-West University (Potchefstroom Campus), Potchefstroom, South Africa
| | - Suria M Ellis
- Statistical Consultation Service, North-West University (Potchefstroom Campus), Potchefstroom, South Africa
| |
Collapse
|
16
|
Neuss M, Gilmore T, Belderson K, Billett A, Conti-Kalchik T, Harvey B, Hendricks C, LeFebvre K, Mangu P, McNiff K, Olsen M, Schulmeister L, Von Gehr A, Polovich M. 2016 Updated American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards, Including Standards for Pediatric Oncology. Oncol Nurs Forum 2017; 44:31-43. [PMID: 28067033 DOI: 10.1188/17.onf.31-43] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Purpose To update the American Society of Clinical Oncology (ASCO)/Oncology Nursing Society (ONS) Chemotherapy Administration Safety Standards and to highlight standards for pediatric oncology. Methods The ASCO/ONS Chemotherapy Administration Safety Standards were first published in 2009 and updated in 2011 to include inpatient settings. A subsequent 2013 revision expanded the standards to include the safe administration and management of oral chemotherapy. A joint ASCO/ONS workshop with stakeholder participation, including that of the Association of Pediatric Hematology Oncology Nurses and American Society of Pediatric Hematology/Oncology, was held on May 12, 2015, to review the 2013 standards. An extensive literature search was subsequently conducted, and public comments on the revised draft standards were solicited. Results The updated 2016 standards presented here include clarification and expansion of existing standards to include pediatric oncology and to introduce new standards: most notably, two-person verification of chemotherapy preparation processes, administration of vinca alkaloids via minibags in facilities in which intrathecal medications are administered, and labeling of medications dispensed from the health care setting to be taken by the patient at home. The standards were reordered and renumbered to align with the sequential processes of chemotherapy prescription, preparation, and administration. Several standards were separated into their respective components for clarity and to facilitate measurement of adherence to a standard. Conclusion As oncology practice has changed, so have chemotherapy administration safety standards. Advances in technology, cancer treatment, and education and training have prompted the need for periodic review and revision of the standards. Additional information is available at http://www.asco.org/chemo-standards.
Collapse
|
17
|
Neuss MN, Gilmore TR, Belderson KM, Billett AL, Conti-Kalchik T, Harvey BE, Hendricks C, LeFebvre KB, Mangu PB, McNiff K, Olsen M, Schulmeister L, Von Gehr A, Polovich M. 2016 Updated American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards, Including Standards for Pediatric Oncology. J Oncol Pract 2016; 12:1262-1271. [DOI: 10.1200/jop.2016.017905] [Citation(s) in RCA: 67] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose To update the ASCO/Oncology Nursing Society (ONS) Chemotherapy Administration Safety Standards and to highlight standards for pediatric oncology. Methods The ASCO/ONS Chemotherapy Administration Safety Standards were first published in 2009 and updated in 2011 to include inpatient settings. A subsequent 2013 revision expanded the standards to include the safe administration and management of oral chemotherapy. A joint ASCO/ONS workshop with stakeholder participation, including that of the Association of Pediatric Hematology Oncology Nurses and American Society of Pediatric Hematology/Oncology, was held on May 12, 2015, to review the 2013 standards. An extensive literature search was subsequently conducted, and public comments on the revised draft standards were solicited. Results The updated 2016 standards presented here include clarification and expansion of existing standards to include pediatric oncology and to introduce new standards: most notably, two-person verification of chemotherapy preparation processes, administration of vinca alkaloids via minibags in facilities in which intrathecal medications are administered, and labeling of medications dispensed from the health care setting to be taken by the patient at home. The standards were reordered and renumbered to align with the sequential processes of chemotherapy prescription, preparation, and administration. Several standards were separated into their respective components for clarity and to facilitate measurement of adherence to a standard. Conclusion As oncology practice has changed, so have chemotherapy administration safety standards. Advances in technology, cancer treatment, and education and training have prompted the need for periodic review and revision of the standards. Additional information is available at http://www.asco.org/chemo-standards .
Collapse
Affiliation(s)
- Michael N. Neuss
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Terry R. Gilmore
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Kristin M. Belderson
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Amy L. Billett
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Tara Conti-Kalchik
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Brittany E. Harvey
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Carolyn Hendricks
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Kristine B. LeFebvre
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Pamela B. Mangu
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Kristen McNiff
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - MiKaela Olsen
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Lisa Schulmeister
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Ann Von Gehr
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Martha Polovich
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| |
Collapse
|
18
|
Schwappach DLB, Pfeiffer Y, Taxis K. Medication double-checking procedures in clinical practice: a cross-sectional survey of oncology nurses' experiences. BMJ Open 2016; 6:e011394. [PMID: 27297014 PMCID: PMC4916573 DOI: 10.1136/bmjopen-2016-011394] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
BACKGROUND Double-checking is widely recommended as an essential method to prevent medication errors. However, prior research has shown that the concept of double-checking is not clearly defined, and that little is known about actual practice in oncology, for example, what kind of checking procedures are applied. OBJECTIVE To study the practice of different double-checking procedures in chemotherapy administration and to explore nurses' experiences, for example, how often they actually find errors using a certain procedure. General evaluations regarding double-checking, for example, frequency of interruptions during and caused by a check, or what is regarded as its essential feature was assessed. METHODS In a cross-sectional survey, qualified nurses working in oncology departments of 3 hospitals were asked to rate 5 different scenarios of double-checking procedures regarding dimensions such as frequency of use in practice and appropriateness to prevent medication errors; they were also asked general questions about double-checking. RESULTS Overall, 274 nurses (70% response rate) participated in the survey. The procedure of jointly double-checking (read-read back) was most commonly used (69% of respondents) and rated as very appropriate to prevent medication errors. Jointly checking medication was seen as the essential characteristic of double-checking-more frequently than 'carrying out checks independently' (54% vs 24%). Most nurses (78%) found the frequency of double-checking in their department appropriate. Being interrupted in one's own current activity for supporting a double-check was reported to occur frequently. Regression analysis revealed a strong preference towards checks that are currently implemented at the responders' workplace. CONCLUSIONS Double-checking is well regarded by oncology nurses as a procedure to help prevent errors, with jointly checking being used most frequently. Our results show that the notion of independent checking needs to be transferred more actively into clinical practice. The high frequency of reported interruptions during and caused by double-checks is of concern.
Collapse
Affiliation(s)
- D L B Schwappach
- Swiss Patient Safety Foundation, Zuerich, Switzerland Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland
| | | | - Katja Taxis
- Department of Pharmacy, Unit of Pharmacotherapy and Pharmaceutical Care, University of Groningen, Groningen, The Netherlands
| |
Collapse
|
19
|
Baldwin A, Rodriguez ES. Improving Patient Safety With Error Identification in Chemotherapy Orders by Verification Nurses. Clin J Oncol Nurs 2016; 20:59-65. [PMID: 26800407 DOI: 10.1188/16.cjon.59-65] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND The prevalence of medication errors associated with chemotherapy administration is not precisely known. Little evidence exists concerning the extent or nature of errors; however, some evidence demonstrates that errors are related to prescribing. This article demonstrates how the review of chemotherapy orders by a designated nurse known as a verification nurse (VN) at a National Cancer Institute-designated comprehensive cancer center helps to identify prescribing errors that may prevent chemotherapy administration mistakes and improve patient safety in outpatient infusion units. OBJECTIVES This article will describe the role of the VN and details of the verification process. METHODS To identify benefits of the VN role, a retrospective review and analysis of chemotherapy near-miss events from 2009-2014 was performed. FINDINGS A total of 4,282 events related to chemotherapy were entered into the Reporting to Improve Safety and Quality system. A majority of the events were categorized as near-miss events, or those that, because of chance, did not result in patient injury, and were identified at the point of prescribing.
Collapse
|
20
|
Oberoi S, Trehan A, Marwaha RK. Medication errors on oral chemotherapy in children with acute lymphoblastic leukemia in a developing country. Pediatr Blood Cancer 2014; 61:2218-22. [PMID: 25175850 DOI: 10.1002/pbc.25203] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/20/2014] [Accepted: 07/07/2014] [Indexed: 11/05/2022]
Abstract
BACKGROUND Medication errors occur universally. Inappropriate administration of chemotherapy drugs can have adverse effects in cancer patients. Our objective was to assess the rate and type of medication errors in children with acute lymphoblastic leukemia (ALL) receiving oral chemotherapy in outpatient setting. PROCEDURE Prescription and administration of oral chemotherapy drugs in children with ALL were evaluated prospectively to determine rate and type of medication errors. Errors were defined as prescription (physician) level or administration (patient) level errors. RESULTS Two hundred eighty-nine drugs were prescribed to 121 patients. Medication errors occurred in 36 (12.5%) prescriptions; 21(7.3%) were administration errors, 13 (4.5%) were prescribing errors, and two errors occurred at both levels. Mercaptopurine (6-MP) was significantly associated with higher rates of errors (Odds ratio [OR] = 2.1, 95% CI [confidence interval] 1-4.1) whereas lapses were less with dexamethasone (OR = 0.25, 95% CI 0.09-0.67). As a result of medication errors 28 (23.1%) patients received inappropriate doses. Twenty five (21%) patients received sub-optimal doses whereas three got higher doses of chemotherapy. On univariate analysis, socioeconomic status, education status of the caregiver, 6-MP and methotrexate were significantly associated with errors (P ≤ 0.05). On multivariate analysis, ≤ primary school education of the caregiver and prescription of methotrexate were independent predictors of errors. CONCLUSIONS Medication errors affected nearly one fourth of the children receiving oral chemotherapy. Future studies are needed to look at effective interventions to avoid chemotherapy associated errors especially amongst the lower strata of society.
Collapse
Affiliation(s)
- Sapna Oberoi
- Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada
| | | | | |
Collapse
|